The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
This study compares the cost effectiveness of Helicobacter pylori eradication and conventional treatment in duodenal ulcer patients treated by a general practitioner. Using a Markov chain approach, Swedish cost data and a study period of 5 years, we conclude that H. pylori eradication with omeprazole and appropriate antibiotics is a cost-effective alternative compared with both maintenance and episodic treatment. Of the patients entering the eradication strategy, most are cured and will have no relapse during a 5-year period. H. pylori eradication results in higher initial costs but, because of a very low risk of recurrence after successful eradication, the expected future costs are reduced. The investment pays off within 1 year when compared with maintenance treatment, and within 3 years when compared with episodic treatment.
Unge
P
P
Sandviken Hospital, Sweden.
Jönsson
B
B
Stålhammar
N O
NO
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008390:Markov Chains; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use; D012008:Recurrence; D013548:Sweden